LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a
biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of
severe genetic rare diseases, today announced that it intends to offer and sell $75,000,000 of its ordinary shares in an
underwritten public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the
underwriters a 30-day option to purchase up to an additional $11,250,000 of ordinary shares, on the same terms and
conditions. The offering is subject to market conditions and other closing conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual terms of the offering.
ProQR intends to use the net proceeds from the offering to fund ongoing research and development activities and for working
capital and other general corporate purposes.
Citigroup, Evercore ISI and RBC Capital Markets are acting as joint bookrunners for the offering.
A shelf registration statement relating to the offered ordinary shares was filed with the Securities and Exchange
Commission (SEC) on October 2, 2015, which was declared effective on October 19, 2015. A preliminary
prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website, located
at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus
relating to the offering may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; Evercore ISI, Attention: Equity Capital
Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at (888) 474-0200 or by email at
ecm.prospectus@evercore.com; or RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY
10281, or by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there
be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such state or jurisdiction.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of
severe genetic rare diseases such as Leber’s congenital amaurosis 10, dystrophic epidermolysis bullosa and cystic fibrosis. Based
on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,”
“goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar
expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to
management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements
about the proposed offering of ProQR’s ordinary shares and the use of proceeds therefrom. These forward-looking statements involve
risks and uncertainties, many of which are beyond ProQR’s control, including risk and uncertainties related to market conditions
and satisfaction of customary closing conditions related to the proposed offering. There can be no assurance that ProQR will be
able to complete the proposed offering on the anticipated terms, or at all. Applicable risks also include those that are included
in ProQR’s preliminary prospectus supplement and accompanying prospectus filed with the SEC for the proposed public offering,
including the documents incorporated by reference therein, which include ProQR’s Annual Report on Form 20-F for the year ended
December 31, 2017, and any subsequent SEC filings. Given these risks, uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new
information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
ir@proqr.com
